A clinical trial to study the impact of TAMA(Treatment Advice by Mobile Alerts) on usage and its patterns in HIV-1 Infected subjects and clinics

A qualitative study to assess the impact of TAMA (Treatment Advice by Mobile Alerts) on usage and usage patterns in HIV-1 infected subjects and clinics.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/12/003228

Enrollment

Registered

2012-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- HIV-1 infected subjects

Interventions

Intervention1: TAMA(Treatment Advice by Mobile Alerts): the IT system with a cell phone interface (intervention group). Frequency: personalized pill reminder call at the time of standard of care (SoC

Total Duration: 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who meet all of the following criteria are eligible for this trial. 1. Male or female adult subjects, aged 18-65 (both years inclusive) years at screening. 2. Confirmed HIV-1 infection. 3. ARV treatment-naÃ¯ve patients on first-line NNRTI-based HAART. 4. Owning a cell phone that is only used by the subject himself/herself. 5. Having the ability to use basic cell phone functions 6. Ability to consent and comply with study procedures. 7. General medical condition, in the investigatorâ??s opinion, does not interfere with the assessments and the completion of the trial. 8. Subjectâ??s preferred language of interaction with TAMA system is one of the languages in which TAMA will be currently made available, i.e., English, Hindi, Marathi, Tamil, Telugu or Kannada.

Exclusion criteria

Exclusion criteria: Subjects must not have any of the following characteristics. 1. Previous exposure to any ARVs (including mother-to-child-transmission prophylaxis) of more than 6 months 2. Presence of acute opportunistic infections. 3. Active alcohol and/or substance abuse. 4. Subject whose clinical condition interferes with appropriate use of cell phone (e.g., deafness, severe cognitive impairment). 5. Participation in any other concurrent interventional study. 6. Any condition (including but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the subjects safety or adherence to the trial protocol. 7. Life expectancy of less than 6 months

Design outcomes

Primary

Measure	Time frame
The primary study objective is to evaluate and analyze patient usage of TAMA over 12 weeksTimepoint: 12 weeks	—

Secondary

Measure	Time frame
NoneTimepoint: None	—

Countries

India

Contacts

Public ContactSuchela Srivatsa

Quintiles Research India Pvt. Ltd

Shoibal.mukherjee@quintiles.com91-7838652395

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026